EHMT1 mediates cellular motility in embryonal rhabdomyosarcoma by activating SOX8 expression
- PMID: 40467997
- PMCID: PMC12322076
- DOI: 10.1038/s41416-025-03066-6
EHMT1 mediates cellular motility in embryonal rhabdomyosarcoma by activating SOX8 expression
Abstract
Background: Rhabdomyosarcoma (RMS) is the most common pediatric soft tissue sarcoma. When metastatic, survival of children with RMS is less than 20% and has remained unchanged over two decades. No targeted drug therapy is available for these cancers. Genomic analysis has revealed a low incidence of somatic mutations in RMS. Epigenetic modifiers thus play important roles in driving oncogenesis. In this study, we examined the role of EHMT1 in fusion- negative embryonal rhabdomyosarcoma (ERMS), the most frequent subtype of RMS.
Methods: We performed transcriptomic and phenotypic analysis in vitro and in vivo using EHMT1 depleted cells as well as that of its target gene SOX8.
Results: EHMT1 was found to enhance migration and invasion of ERMS cells in vitro and metastasis in vivo. SOX8, a transcription factor that has key roles in cellular motility was significantly decreased upon EHMT1 loss. Consistently, SOX8 depletion phenotypically mimicked EHMT1 loss. Moreover, RNA Sequencing of SOX8 depleted cells showed down regulation of several integrin genes. Mechanistically, EHMT1 was found to upregulate SOX8 via regulation of BRD4 expression, and consequently increased BRD4 occupancy at the SOX8 promoter.
Conclusion: Our study reveals a novel EHMT1-SOX8 axis that mediates metastasis in ERMS.
© 2025. The Author(s), under exclusive licence to Springer Nature Limited.
Conflict of interest statement
Competing interests: The authors declare no competing interests. Ethics approval and consent to participate: All methods were performed in accordance with the relevant guidelines and regulations. All animal procedures were approved by Institutional Animal Care and Use Committee under protocol number R20-0994.
Similar articles
-
Focal adhesion kinase (FAK) phosphorylation is a key regulator of embryonal rhabdomyosarcoma (ERMS) cell viability and migration.J Cancer Res Clin Oncol. 2019 Jun;145(6):1461-1469. doi: 10.1007/s00432-019-02913-3. Epub 2019 Apr 21. J Cancer Res Clin Oncol. 2019. PMID: 31006845 Free PMC article.
-
Alterations of RB1 gene in embryonal and alveolar rhabdomyosarcoma: special reference to utility of pRB immunoreactivity in differential diagnosis of rhabdomyosarcoma subtype.J Cancer Res Clin Oncol. 2008 Oct;134(10):1097-103. doi: 10.1007/s00432-008-0385-3. Epub 2008 Apr 2. J Cancer Res Clin Oncol. 2008. PMID: 18386058 Free PMC article.
-
SETD6 mediates selective interaction and genomic occupancy of BRD4 and MITF in melanoma cells.NAR Cancer. 2025 Aug 7;7(3):zcaf023. doi: 10.1093/narcan/zcaf023. eCollection 2025 Sep. NAR Cancer. 2025. PMID: 40809945 Free PMC article.
-
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4. Cochrane Database Syst Rev. 2021. Update in: Cochrane Database Syst Rev. 2022 May 23;5:CD011535. doi: 10.1002/14651858.CD011535.pub5. PMID: 33871055 Free PMC article. Updated.
-
The Black Book of Psychotropic Dosing and Monitoring.Psychopharmacol Bull. 2024 Jul 8;54(3):8-59. Psychopharmacol Bull. 2024. PMID: 38993656 Free PMC article. Review.
References
-
- Galili N, Davis RJ, Fredericks WJ, Mukhopadhyay S, Rauscher FJ, Emanuel BS, et al. Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma. Nat Genet. 1993;5:230–5. - PubMed
-
- Bennicelli JL, Fredericks WJ, Wilson RB, Rauscher FJ, Barr FG. Wild type PAX3 protein and the PAX3-FKHR fusion protein of alveolar rhabdomyosarcoma contain potent, structurally distinct transcriptional activation domains. Oncogene. 1995;11:119–30. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources